Insmed (INSM)
(Delayed Data from NSDQ)
$56.85 USD
-0.32 (-0.56%)
Updated Jun 7, 2024 04:00 PM ET
After-Market: $56.86 +0.01 (0.02%) 7:58 PM ET
3-Hold of 5 3
F Value D Growth A Momentum F VGM
Brokerage Reports
0 items in cart
Insmed, Inc. [INSM]
Reports for Purchase
Showing records 41 - 60 ( 113 total )
Company: Insmed, Inc.
Industry: Medical - Biomedical and Genetics
Company: Insmed, Inc.
Industry: Medical - Biomedical and Genetics
What to Expect When You''re Expecting; Diligence Culled from Recent Filings and KOL Feedback Ahead of the ALIS PDUFA Date
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Insmed, Inc.
Industry: Medical - Biomedical and Genetics
Company: Insmed, Inc.
Industry: Medical - Biomedical and Genetics
Thoughts Following Release of Briefing Documents
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Insmed, Inc.
Industry: Medical - Biomedical and Genetics
Company: Insmed, Inc.
Industry: Medical - Biomedical and Genetics
ALIS AdCom Coming in Early August, We Believe; Reit Buy
Provider: H.C. Wainwright & Co., Inc.
Company: Insmed, Inc.
Industry: Medical - Biomedical and Genetics
Our Take on the Japanese Respiratory Society Meeting and the Path Ahead; Reit Buy and $35 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Insmed, Inc.
Industry: Medical - Biomedical and Genetics
Company: Insmed, Inc.
Industry: Medical - Biomedical and Genetics
Data and Lack of a Japanese Licensing Deal Ought to Continue to Assuage Concerns; Reit Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Insmed, Inc.
Industry: Medical - Biomedical and Genetics
Company: Insmed, Inc.
Industry: Medical - Biomedical and Genetics
Looking Ahead to 2018 and Thinking Beyond NTM; Reit Buy and $35 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Insmed, Inc.
Industry: Medical - Biomedical and Genetics
Company: Insmed, Inc.
Industry: Medical - Biomedical and Genetics
Thinking About Stats Ahead of CONVERT Study Read Out
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Insmed, Inc.
Industry: Medical - Biomedical and Genetics
Takeaways From Analyst Day: Reit Buy Rating and $35 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Insmed, Inc.
Industry: Medical - Biomedical and Genetics
Company: Insmed, Inc.
Industry: Medical - Biomedical and Genetics
Contemplating an M-A Scenario Prior to Topline Data
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Insmed, Inc.
Industry: Medical - Biomedical and Genetics
Company: Insmed, Inc.
Industry: Medical - Biomedical and Genetics
Enrollment Completion Refreshes NTM Value Proposition
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A